Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.
HER2
endocrine resistance
estrogen receptor
fatty acid synthase
tamoxifen
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Mar 2021
06 Mar 2021
Historique:
received:
16
02
2021
revised:
02
03
2021
accepted:
03
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
The identification of clinically important molecular mechanisms driving endocrine resistance is a priority in estrogen receptor-positive (ER+) breast cancer. Although both genomic and non-genomic cross-talk between the ER and growth factor receptors such as human epidermal growth factor receptor 2 (HER2) has frequently been associated with both experimental and clinical endocrine therapy resistance, combined targeting of ER and HER2 has failed to improve overall survival in endocrine non-responsive disease. Herein, we questioned the role of fatty acid synthase (FASN), a lipogenic enzyme linked to HER2-driven breast cancer aggressiveness, in the development and maintenance of hormone-independent growth and resistance to anti-estrogens in ER/HER2-positive (ER+/HER2+) breast cancer. The stimulatory effects of estradiol on
Identifiants
pubmed: 33800852
pii: cancers13051132
doi: 10.3390/cancers13051132
pmc: PMC7961649
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA116623
Pays : United States
Organisme : U.S. Department of Defense
ID : BC151072
Organisme : U.S. Department of Defense
ID : BC151072P1
Organisme : Ministerio de Ciencia e Innovación
ID : SAF2016-80639-P
Organisme : Ministerio de Ciencia e Innovación
ID : PID2019-10455GB-I00
Références
Future Med Chem. 2015 Aug;7(12):1511-9
pubmed: 26306654
Breast Cancer Res Treat. 2007 Mar;102(1):43-9
pubmed: 16897431
Oncogene. 2004 Jun 17;23(28):4945-58
pubmed: 15094777
J Natl Cancer Inst. 2007 May 2;99(9):694-705
pubmed: 17470737
J Mol Endocrinol. 2008 Nov;41(5):367-77
pubmed: 18768663
Nat Methods. 2013 Nov;10(11):1046-7
pubmed: 24037243
J Clin Oncol. 2009 Nov 20;27(33):5538-46
pubmed: 19786658
Breast Cancer Res. 2011 Jan 24;13(1):401
pubmed: 21349137
Steroids. 2009 Jul;74(7):586-94
pubmed: 19138696
Clin Cancer Res. 2005 Jul 15;11(14):5319-28
pubmed: 16033851
Future Oncol. 2010 Apr;6(4):551-62
pubmed: 20373869
J Transl Med. 2015 May 07;13:146
pubmed: 25947066
Clin Chem. 2009 Mar;55(3):425-38
pubmed: 19181734
Cancer Res. 2017 Nov 1;77(21):e51-e54
pubmed: 29092939
J Clin Oncol. 2003 May 15;21(10):1967-72
pubmed: 12743150
Int J Oncol. 2005 Jun;26(6):1507-15
pubmed: 15870863
Clin Cancer Res. 2004 Jun 1;10(11):3621-8
pubmed: 15173068
Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016
pubmed: 28922023
Nat Rev Cancer. 2016 Nov;16(11):732-749
pubmed: 27658529
Curr Opin Pharmacol. 2018 Aug;41:59-65
pubmed: 29719270
Breast Cancer. 2018 Jul;25(4):392-401
pubmed: 29086897
Oncoscience. 2016 Jul 22;3(7-8):242-257
pubmed: 27713913
FASEB J. 2020 Sep;34(9):11355-11381
pubmed: 32761847
Int J Oncol. 2007 Oct;31(4):769-76
pubmed: 17786307
Int J Cancer. 2002 Jan 20;97(3):306-12
pubmed: 11774281
Oncology. 2009;77 Suppl 1:23-37
pubmed: 20130429
Breast Cancer Res. 2018 Sep 4;20(1):106
pubmed: 30180878
Breast Cancer Res Treat. 1992;24(2):85-95
pubmed: 8095168
J Lipid Res. 2013 Mar;54(3):776-85
pubmed: 23319743
J Clin Oncol. 2009 Jun 1;27(16):2630-7
pubmed: 19380449
Breast Cancer Res. 2014 Dec 12;16(6):494
pubmed: 25928204
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12975-80
pubmed: 9371785
PLoS One. 2015 Jun 24;10(6):e0131241
pubmed: 26107737
Histol Histopathol. 2017 Jul;32(7):687-698
pubmed: 27714708
Front Endocrinol (Lausanne). 2019 Aug 21;10:573
pubmed: 31496995
Breast Cancer Res. 2011;13(6):R131
pubmed: 22177475
J Clin Oncol. 2009 Nov 20;27(33):5529-37
pubmed: 19786670
Cancer Treat Rev. 2014 Aug;40(7):862-71
pubmed: 24774538
Mol Endocrinol. 2001 Oct;15(10):1817-28
pubmed: 11579213
Int J Mol Sci. 2020 Oct 16;21(20):
pubmed: 33081219
Oncogenesis. 2017 Feb 27;6(2):e299
pubmed: 28240737
Endocrinology. 2006 Sep;147(9):4056-66
pubmed: 16809439
J Clin Oncol. 2007 Apr 1;25(10):1239-46
pubmed: 17401012
Oncogene. 2000 Oct 26;19(45):5173-81
pubmed: 11064454
Nat Rev Cancer. 2007 Oct;7(10):763-77
pubmed: 17882277
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3450-4
pubmed: 10716717
EBioMedicine. 2017 Feb;16:51-62
pubmed: 28159572
Endocrinology. 2003 Mar;144(3):1032-44
pubmed: 12586780
EBioMedicine. 2015 Jul 02;2(8):808-24
pubmed: 26425687
Int J Cancer. 2018 Aug 15;143(4):992-1002
pubmed: 29569717
Clin Cancer Res. 2015 Dec 15;21(24):5434-8
pubmed: 26519059
Pharmacol Ther. 2017 Sep;177:23-31
pubmed: 28202364
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35
pubmed: 15199112
Mol Cell Proteomics. 2019 Aug 9;18(8 suppl 1):S15-S25
pubmed: 31201206
EMBO Rep. 2019 Feb;20(2):
pubmed: 30665944
BMC Med Genomics. 2009 Jun 24;2:37
pubmed: 19552798
Adv Biol Regul. 2014 Jan;54:214-21
pubmed: 24080588